Julia Sidenius Johansen

Julia Sidenius Johansen

Clinical Professor

Member of:

  • Clinical Oncology


  1. 2016
  2. Published

    Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA)

    Hørslev-Petersen, K., Hetland, M. L., Ørnbjerg, L. M., Junker, P., Pødenphanth, J., Ellingsen, T., Ahlquist, P., Lindegaard, H., Linauskas, A., Schlemmer, A., Dam, M. Y., Hansen, I., Lottenburger, T., Ammitzbøll, C. G., Jørgensen, A., Krintel, S. B., Raun, J., Johansen, J. S., Østergaard, M., Stengaard-Pedersen, K. & 1 others, OPERA Study-Group, O. S., 2016, In: Annals of the Rheumatic Diseases. 75, 9, p. 1645-1653 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer

    Thomsen, M., Kersten, C., Sorbye, H., Skovlund, E., Glimelius, B., Pfeiffer, P., Johansen, Julia Sidenius, Kure, E. H., Ikdahl, T., Tveit, K. M., Christoffersen, T. & Guren, T. K., 2016, In: OncoTarget. 7, 46, p. 75013-75022 10 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Published

    Multi-Biomarker Disease Activity (MBDA) Score and Prediction of Radiographic Progression in a Randomized Study of Patients with Early RA Treated with Methotrexate Alone or with Adalimumab

    Brahe, C. H., Østergaard, M., Johansen, J. S., Defranoux, N. A., Hwang, C. C., Wang, X., Bolce, R. J., Sasso, E. H., Hørslev-Petersen, K., Stengaard-Pedersen, K., Ørnbjerg, L. M., Junker, P., Ellingsen, T., Ahlquist, P., Lindegaard, H., Linauskas, A., Schlemmer, A., Dam, M. Y., Hansen, I. T., Lottenburger, T. & 5 others, Ammitzbøll, C. G., Jørgensen, A., Krintel, S. B., Raun, J. L. & Hetland, Merete Lund, 2016, In: Arthritis & Rheumatology. 68, S10, 4 p., 2520.

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  5. Published

    Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease: Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry

    Glintborg, B., Kringelbach, T. M., Høgdall, Estrid Vilma Solyom, Sørensen, I. J., Jensen, D. V., Loft, A. G., Hendricks, O., Jensen Hansen, I. M., Bolstad, N., Grøn, K., Eng, G., Enevold, C., Nielsen, C. H., Warren, D., Goll, G., Gehin, J., Johansen, Julia Sidenius & Hetland, Merete Lund, 2016, In: Annals of the Rheumatic Diseases. 75, Suppl 2, 1 p., THU0123 .

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  6. Published

    Non-Medical Switch from Originator to Biosimilar Infliximab in Patients with Inflammatory Arthritis: Impact on s-Infliximab and Antidrug-Antibodies. Results from the Danish Rheumatologic Biobank and the Danbio Registry

    Glintborg, B., Kringelbach, T. M., Høgdall, E. V. S., Sørensen, I. J., Jensen, D. V., Loft, A. G., Hendricks, O., Hansen, I. M. J., Linauskas, A., Kristensen, S., Lindegaard, H., Nordin, H., Bolstad, N., Warren, D., Gehin, J., Goll, G. L., Grøn, K. L., Eng, G., Enevold, C., Nielsen, C. H. & 2 others, Johansen, Julia Sidenius & Hetland, Merete Lund, 2016, In: Arthritis & Rheumatology. 68, S10, 4 p., 1997.

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  7. Published

    Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis

    Krintel, S. B., Dehlendorff, C., Hetland, M. L., Hørslev-Petersen, K., Andersen, K. K., Junker, P., Pødenphant, J., Ellingsen, T., Ahlquist, P., Lindegaard, H. M., Linauskas, A., Schlemmer, A., Dam, M. Y., Hansen, I., Horn, H. C., Jørgensen, A., Raun, J., Ammitzbøll, C. G., Østergaard, M., Stengaard-Pedersen, K. & 1 others, Johansen, Julia Sidenius, 2016, In: Pharmacogenomics Journal. 16, 2, p. 141-6 6 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  8. Published

    Role of inflammatory marker YKL-40 in the diagnosis, prognosis and cause of cardiovascular and liver diseases

    Kjaergaard, A. D., Johansen, Julia Sidenius, Bojesen, Stig Egil & Nordestgaard, Børge, 2016, In: Critical Reviews in Clinical Laboratory Sciences. 53, 6, p. 396-408 13 p.

    Research output: Contribution to journalReviewResearchpeer-review

  9. Published

    YKL-40 in allogeneic hematopoietic cell transplantation after AML and myelodysplastic syndrome

    Kornblit, B., Wang, T., Lee, S. J., Spellman, S. R., Zhu, X., Fleischhauer, K., Müller, C., Verneris, M. R., Muller, Klaus, Johansen, Julia Sidenius, Vindeløv, L. & Garred, Peter, 2016, In: Bone. 51, 12, p. 1556-1560 5 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  10. Published

    The inflammatory biomarker YKL-40 decreases stepwise after exercise stress test

    Dam Mygind, N., Axelsson, A., Ruwald, M. H., Dalsgaard, M., Steffensen, R., Iversen, Kasper, Johansen, Julia Sidenius & Kastrup, J., Mar 2016, In: Cardiovascular Endocrinology. 5, 1, p. 21-27 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  11. Published

    Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression

    Laklai, H., Miroshnikova, Y. A., Pickup, M. W., Collisson, E. A., Kim, G. E., Barrett, A. S., Hill, R. C., Lakins, J. N., Schlaepfer, D. D., Mouw, J. K., LeBleu, V. S., Roy, N., Novitskiy, S. V., Johansen, J. S., Poli, V., Kalluri, R., Iacobuzio-Donahue, C. A., Wood, L. D., Hebrok, M., Hansen, K. & 2 others, Moses, H. L. & Weaver, V. M., May 2016, In: Nature Medicine. 22, 5, p. 497-505 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

Previous 1 2 Next

ID: 13762833